Figure 5From: Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial Start- and end- monthly ESA dose, C.E.R.A. Starting and end-monthly dose of C.E.R.A at 4 weeks (Q4W) and 2 weeks (Q2W) administration intervals. Boxes represent 25th and 75th percentiles, whiskers 5th and 95th percentiles. N = 19.Back to article page